Get Molecular Testing - Ontario
As of July 1st, 2024, Ontario patients living with cholangiocarcinoma will be able to access molecular testing from UHN’s Laboratory Medicine Program (UHN-LMP), in partnership with the C3. UHN-LMP uses a “Custom Solid Tumour (CST) v1 Panel”, which can detect FGFR2 fusions and additional DNA/RNA biomarkers (see below for full list).
Patients and treating physician will receive a complete clinical report indicating Tier I (variants of strong clinical significance) and Tier II (variants of potential clinical significance) alterations in DNA and RNA biomarkers.
​
To be eligible for C3 funded testing, the patient must be a member of the C3 and physicians must submit a C3 Patient Attestation form and UHN-LMP Test Requisition Form.
Important Information:
-
Patients must be a "C3 Patient Member"
-
Please fill out the C3 Attestation form and refer your patients to fill out the C3 Intake form
-
-
On Page 1 of the UHN-C3 Test Requisition Form​, you will find information on Sample Requirements
-
On Page 2 of the UHN-C3 Test Requisition Form, please check only "Cholangiocarcinoma (Hepatobiliary)"​
​ *Note: testing through C3 will also return the list of genes at the bottom of this page, even though the TRF says "FGFR2 Only"​
-
Please notify the C3 about test orders by filling out the C3 notification form
-
Completed Test Requisition Forms should be sent to:
-
Toronto General Hospital​
Eaton Wing 11-444, 200 Elizabeth Street
Toronto, Ontario, M5G 2C4
Attn: Dr. Shamini Selvarajah
Phone: (416) 340-4800 x5739
Fax: (416) 340-4473 Genome Diagnostics
Email: Genome.diagnostics@uhn.ca
-
Forms for UHN-LMP x C3
Contact and Assistance Information:
Answers to FAQ
-
The patient will get a clinical grade NGS report including FGFR fusions and additional relevant BTC targets
-
note: CCO funded testing reports only FGFR
-
See bottom of page for all targets
-
-
Patients need to register with C3 by contacting c3@ohri.ca or providing permission for the C3 to contact them
-
Patients do not have to be seen at UHN in order to receive testing
*UHN-LMP provides Clinical-Grade Molecular Testing (CAP# 7175217/CLIA# 99D1106115)